During the third quarter, Bank Pictet & Cie Europe AG boosted its holdings in Gilead Sciences by 502.8%, acquiring an additional 12,752 shares to reach a total position of 15,288 shares valued at approximately 1.697 million. Invesco Ltd. expanded its stake by 33.5% in the second quarter, adding 3.39 million shares to hold 13.52 million shares worth roughly 1.499 billion. Other notable moves include Sivik Global Healthcare LLC increasing its position by 25.0% to 50,000 shares, One Wealth Advisors LLC adding 2,364 shares for a 34.8% gain, and Lombard Odier Asset Management Switzerland SA purchasing 10,535 shares for a 24.6% rise. Institutional ownership now stands at 83.67% of the company’s outstanding shares.

In its latest quarterly report, Gilead Sciences reported earnings per share of 2.47, surpassing the consensus estimate of 2.16 by 0.31. Revenue reached 7.77 billion, topping forecasts by 350 million and representing a 3.0% year-over-year increase. Return on equity was reported at 51.86% and net margin at 27.88%. Management provided full-year 2025 guidance of 8.05 to 8.25 earnings per share, while analysts project 7.95 EPS for the current fiscal year.

Gilead declared a quarterly dividend of 0.79 per share, payable to shareholders of record on December 15th, resulting in an annualized payout of 3.16 and a yield of approximately 2.6%. The company’s payout ratio stands at 48.99%. In the past quarter, insiders sold 136,257 shares valued at 16.86 million, including sales by the CFO of 3,000 shares and a board director of 5,000 shares, representing declines of 1.92% and 35.92% in their respective holdings.

Wall Street sentiment has become more positive, with Rothschild & Co Redburn raising its price target from 143.00 to 153.00 and Goldman Sachs lifting its objective from 108.00 to 110.00 with a neutral rating. DBS Bank assigned a moderate buy rating, Citigroup increased its target from 125.00 to 135.00 and issued a buy rating, and Scotiabank initiated coverage with a sector outperform rating and a 140.00 target. Of the 28 analysts covering Gilead, two hold strong buy ratings, 22 rate the stock as a buy, and four as a hold, yielding an average target of 131.68 and an overall moderate buy consensus.